drugset / Trial / NCT00904059

Drug-Drug Interaction Study in Healthy Subjects

NCT00904059

Phase 1 Completed 28 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to assess the pharmacokinetics and safety of BMS-790052 and BMS-650032 when co-administered and when administered alone

Timeline

Start
2009-05
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Asunaprevir Small molecule 200 mg Oral
Subject Asunaprevir Small molecule 600 mg Oral
Subject Daclatasvir Small molecule 30 mg Oral
Subject Daclatasvir Small molecule 60 mg Oral